Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay Singh

Showing results (561-570 of 575) with videos related to

Pageof 58
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based ChemoradiationVijay Maruti Patil, Vanita Noronha, Nandini Menon, et al.
Medrxiv : the Preprint Server for Health Sciences|November 22, 2024
International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from population-based cross-sectional studies: a disadvantaged populations eGFR epidemiology (DEGREE) studyCharlotte E Rutter, Mary Njoroge, Phil Cooper, et al.
Kidney International|December 21, 2024
International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) studyCharlotte E Rutter, Mary Njoroge, Philip J Cooper, et al.
Nature Communications|November 28, 2024
Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus MacaquesSommer Holmes, Hui Li, Xiaoying Shen, et al.
Cell Reports|June 14, 2025
Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaquesDaniel J Morris, Jason Gorman, Tongqing Zhou, et al.
Biorxiv : the Preprint Server for Biology|January 13, 2025
Transient glycan-shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaquesDaniel J Morris, Jason Gorman, Tongqing Zhou, et al.
Biorxiv : the Preprint Server for Biology|June 21, 2024
HIV-1 neutralizing antibodies in SHIV-infected macaques recapitulate structurally divergent modes of human V2 apex recognition with a single D geneRyan S Roark, Rumi Habib, Jason Gorman, et al.
The Journal of Experimental Medicine|August 18, 2025
Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodiesRyan S Roark, Rumi Habib, Jason Gorman, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2024
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancerVanita Noronha, Vijay Patil, Pankaj Chaturvedi, et al.
Science Immunology|February 13, 2026
Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody developmentRumi Habib, Ryan S Roark, Hui Li, et al.
Pageof 58

Showing results (561-570 of 575) with videos related to

Sort By:
Pageof 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based ChemoradiationVijay Maruti Patil, Vanita Noronha, Nandini Menon, et al.
Medrxiv : the Preprint Server for Health Sciences|November 22, 2024
International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from population-based cross-sectional studies: a disadvantaged populations eGFR epidemiology (DEGREE) studyCharlotte E Rutter, Mary Njoroge, Phil Cooper, et al.
Kidney International|December 21, 2024
International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) studyCharlotte E Rutter, Mary Njoroge, Philip J Cooper, et al.
Nature Communications|November 28, 2024
Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus MacaquesSommer Holmes, Hui Li, Xiaoying Shen, et al.
Cell Reports|June 14, 2025
Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaquesDaniel J Morris, Jason Gorman, Tongqing Zhou, et al.
Biorxiv : the Preprint Server for Biology|January 13, 2025
Transient glycan-shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaquesDaniel J Morris, Jason Gorman, Tongqing Zhou, et al.
Biorxiv : the Preprint Server for Biology|June 21, 2024
HIV-1 neutralizing antibodies in SHIV-infected macaques recapitulate structurally divergent modes of human V2 apex recognition with a single D geneRyan S Roark, Rumi Habib, Jason Gorman, et al.
The Journal of Experimental Medicine|August 18, 2025
Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodiesRyan S Roark, Rumi Habib, Jason Gorman, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2024
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancerVanita Noronha, Vijay Patil, Pankaj Chaturvedi, et al.
Science Immunology|February 13, 2026
Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody developmentRumi Habib, Ryan S Roark, Hui Li, et al.
Pageof 58